(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
How to watch 'A Charlie Brown Christmas' for less with this Apple TV Black Friday deal - 2Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- 3The biggest black hole breakthroughs of 2025
- 4Guaranteeing Quality Medical care with Federal medical care Benefit Plans.
- 5More than half way to the moon, the Artemis II astronauts are grappling with a toilet problem
- Genetic study identifies earliest-known dog, dating to 15,800 years ago
- Can a mammogram help identify heart disease?
- IDF Givati Brigade soldier arrested, charged in suspected Iran espionage
- $30K Disability Scam Implodes After Surf Trip in Mexico
- Find Successful Magnificence Items for Sparkling Skin
- Italy now recognizes the crime of femicide and punishes it with life in prison
- Reporter's notebook: Inside the IDF’s ‘Hamas Village,’ and how Israel is rewriting urban warfare
- How to watch the last supermoon of the year
- 6 Famous Urban communities for Shopping on the planet
